SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
SHIRE BIOCHEM INC

(Last) (First) (Middle)
275 ARMAND-FRAPPIER BLVD

(Street)
LAVAL QUEBEC E6 H7V 4A7

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
05/13/2003
3. Issuer Name and Ticker or Trading Symbol
IMMUNOGEN INC [ IMGN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 4,096,098 D(1)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
SHIRE BIOCHEM INC

(Last) (First) (Middle)
275 ARMAND-FRAPPIER BLVD

(Street)
LAVAL QUEBEC E6 H7V 4A7

(City) (State) (Zip)
1. Name and Address of Reporting Person*
SHIRE PHARMACEUTICALS GROUP PLC

(Last) (First) (Middle)
HAMPSHIRE INTL BUSINESS PARK
CHINEHAM BASINGSTOKE

(Street)
HAMPSHIRE ENGLAND RG X0

(City) (State) (Zip)
Explanation of Responses:
1. These shares are owned directly by Shire BioChem Inc., which is a wholly owned subsidiary of Shire Pharmaceuticals Group plc. Shire Pharmaceuticals Group plc is an indirect beneficial owner of the reported securities.
Remarks:
Exhibit 99 - Joint Filer Information
/s/ Joseph Rus, President & CEO, Shire BioChem Inc. 08/06/2003
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                         Form 3 Joint Filer Information


Name:    Shire Pharmaceuticals Group plc

Address: Hampshire International Business Park
                  Chineham, Basingstoke
                  Hampshire, England  RG24 8EP

Designated Filer: Shire BioChem Inc.

Issuer & Ticker Symbol:    ImmunoGen, Inc. (IMGN)

Date of Event Requiring Statement:  May 13, 2003


Signature:        /s/ Angus Charles Russell
                  ----------------------------------
                  Name:  Angus Charles Russell
                  Title:  Group Finance Director